06 Jan, 2023 Inflation Reduction Act: Discussion About the Mixed Effect on Costs for Drugs By Kirsten Axelsen The American Enterprise Institute (AEI), a public policy think tank, published a piece this week by Kirsten Axelsen on the potential cost...
28 Oct, 2022 Considering Modifications to Existing FDA Regulatory Incentives to Achieve Greater Racial and Ethnic Diversity in Clinical Trials for Drug Approvals By Kirsten Axelsen When clinical trials for new drug approvals fail to adequately represent racial and ethnic groups, there is a lost opportunity to collect...
03 Mar, 2022 Incentivizing diverse representation in clinical trials: At the Intersection of Science and Law Podcast Series By Kirsten Axelsen Sarah Schick Diverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. In this episode, DLA...
08 Feb, 2022 An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation By Kirsten Axelsen Having previously examined the impact of implementing international reference pricing in the United States, Charles River Associates (a...
14 Dec, 2021 Drug price controls make industry critics feel better, but won’t make people feel healthier By Kirsten Axelsen Please note: Article was first published in The American Enterprise Institute for Public Policy Research In Build Back Better, price...
17 Nov, 2021 Assessing the value of medicine for diverse patients: Implications of a QALY approach for health disparities By Kirsten Axelsen Momentum and debate about the application of cost-effectiveness analysis to determine the value and prices of prescription drugs in the...
13 Jul, 2021 Use of preventive care services declined despite expanded coverage By Kirsten Axelsen Key Points: For the privately insured, Medicare, and uninsured populations, the prevalence of the use of preventive care services...